A. Leselbaum

发表

Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study

E. Bateman, Dave Singh, P. Jones, 2014, BMC Pulmonary Medicine.

Pharmacokinetics of aclidinium bromide/formoterol fumarate fixed‐dose combination compared with individual components: A phase 1, open‐label, single‐dose study

A. Leselbaum, J. Aubets, R. Fuhr, 2016, Clinical pharmacology in drug development.

Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study

E. Kerwin, S. Rennard, C. Caracta, 2014, Respiratory Research.

Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study

C. Vogelmeier, P. Śliwiński, A. Leselbaum, 2016, European Respiratory Journal.

A randomised double-blind, placebo-controlled, long-term extension study of the efficacy, safety and tolerability of fixed-dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease.

E. Kerwin, S. Rennard, E. Molins, 2017, Respiratory medicine.

Long-term Safety of a Fixed-Dose Combination of Aclidinium Bromide/Formoterol Fumarate in Patients With Stable Moderate to Severe COPD

B. Make, C. Caracta, A. Leselbaum, 2014 .

The AUGMENT COPD Trial: Efficacy and Safety of a Fixed-Dose Combination of Aclidinium Bromide and Formoterol Fumarate in COPD Patients

S. Rennard, C. Caracta, E. G. Gil, 2014 .

Efficacy and safety of fixed-dose combination aclidinium bromide/formoterol fumarate in patients with COPD: Results from the AUGMENT COPD trial

C. Caracta, A. Leselbaum, A. D’Urzo, 2013 .

Evaluation of the Efficacy and Safety of Two Doses of Aclidinium and Formoterol in Fixed-Dose Combination in Patients With COPD: The ACLIFORM Study

E. Bateman, Dave Singh, P. Jones, 2014 .

Safety of aclidinium bromide/formoterol fumarate fixed dose combination (FDC) in COPD: Pooled analyses of three phase III studies

E. Kerwin, S. Korn, A. Leselbaum, 2014 .

Pharmacokinetic profile of lanreotide Autogel® in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days

A. Leselbaum, M. Bronstein, J. Cendros, 2005, Clinical endocrinology.

A phase III randomised controlled trial of Cx601, expanded allogeneic adipose-derived mesenchymal stem cells (eASC), for complex perianal fistulas in Crohn's disease

M. Ferrante, A. Leselbaum, W. Reinisch, 2016 .

Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease.

M. Ferrante, G. Van Assche, A. Leselbaum, 2017, Gastroenterology.

Toxoplasma pericarditis in acquired immunodeficiency syndrome

A. Leselbaum, C. Guérot, E. Guérot, 1995, Intensive Care Medicine.

Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on Lanreotide in Acromegaly.

P. Chanson, A. Leselbaum, G. Schaison, 2000, Pituitary.

Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial

M. Ferrante, A. Leselbaum, W. Reinisch, 2016, The Lancet.

Efficacy and Tolerability of the Long-Acting Somatostatin Analog Lanreotide in Acromegaly. A 12-Month Multicenter Study of 58 Acromegalic Patients

P. Chanson, A. Leselbaum, G. Schaison, 2000, Pituitary.

Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT)

E. Bateman, Dave Singh, E. Molins, 2015, Respiratory Research.

Efficacy of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in COPD

C. Vogelmeier, P. Śliwiński, A. Leselbaum, 2015 .

Effect of aclidinium bromide/formoterol fumarate fixed-dose combination (FDC) on exacerbations in moderate-to-severe COPD: Pooled analysis of two studies

E. Bateman, S. Rennard, P. Jones, 2014 .